Pacira BioSciences Stock Price Prediction – Pacira BioSciences Inc is a well-known pain management and regenerative health company that operates in the United States. If you are considering investing in Pacira BioSciences Inc. stock for the long term, it is important to analyze its potential growth and performance.

Our Pacira BioSciences Inc Stock Forecast is based on a deep technical analysis and past performance of Pacira BioSciences Inc Stock to help you make an informed decision.

To begin with, it is essential to understand Pacira BioSciences Inc’s business model and financial data. Once you have a clear understanding of the company’s operations and financial strength, you can determine whether Pacira BioSciences Inc stock is a good buy or not.

Our Pacira BioSciences Inc Stock Price Forecast covers the stock’s potential growth and performance for the years 2024, 2025, 2030, and 2040 to help you make an informed investment decision.

About Pacira BioSciences Inc

Pacira BioSciences Inc Company Overview – Pacira BioSciences, Inc. is a company that provides solutions for pain management and regenerative health. They offer different options for healthcare practitioners and their patients to manage pain without using opioids. These options include EXPAREL, which is a type of injection that uses tiny particles to numb the area and ZILRETTA, which is a type of injection that slowly releases medicine over time.

They also offer iovera system, which is a handheld device that uses cold temperatures to ease pain in specific areas.

Pacira BioSciences, Inc. is a pharmaceutical company headquartered in Tampa, Florida. They specialize in developing a unique technology that helps deliver drugs directly to the body without changing their structure. This technology is called multivesicular liposome, and it’s designed to make the delivery of drugs more efficient and effective.

The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.

Read More – Riding the AI Melody: Soundhound Stock Price Prediction 2030 2040 2050 2060– Positive Surges Await

Financial Overview of Pacira BioSciences Inc

Here are the Pacira BioSciences Inc Financials –

Pacira BioSciences Inc Stock Price Chart

Pacira BioSciences Inc Revenue

Pacira BioSciences Inc Revenue Chart

Pacira BioSciences Inc Revenue History

Growth Opportunities with Pacira BioSciences Inc

Let’s explore the growth opportunities for investing in Pacira BioSciences, Inc. (NASDAQ: PCRX) –

1. Innovative Pain Management Solutions
2. Strong Revenue Growth
3. Strategic Acquisitions
4. Market Expansion
5. Regulatory Support
6. Commitment to Patient Well-Being

Details are as –

Innovative Pain Management Solutions – Pacira is a company that offers non-opioid pain management solutions. Their flagship product, EXPAREL, is designed to provide long-lasting relief from pain after surgery. As the world moves towards reducing opioid dependency, Pacira’s innovative solutions position the company for growth.

Strong Revenue Growth – Pacira achieved record sales of $507 million in 2021 with its innovative pain management solution, EXPAREL. Over 10 million patients have benefited from this product, reflecting the increasing adoption of Pacira’s products.

Strategic Acquisitions – Pacira recently acquired Flexion Therapeutics, which helped to improve its financial position. This strategic acquisition also provides Pacira with a competitive advantage and diversifies its portfolio.

Market Expansion – Pacira is planning to broaden its market reach by launching EXPAREL in lower extremity nerve blocks in 2024, which is expected to open up additional revenue streams.

Regulatory Support – The NOPAIN Act will improve patient access to non-opioid pain management solutions. Pacira will benefit from this legislative support.

Commitment to Patient Well-Being – The main points of the text are that Pacira is a company that focuses on patient outcomes and safety, which aligns with current healthcare trends. Investors can be confident in supporting the company because of its priority on patient care.

Challenges and Risks associated with Pacira BioSciences Inc

When evaluating the risks associated with investing in Pacira BioSciences, Inc., it’s essential to consider both financial and industry-specific factors. Let’s explore these risks:

1. Debt Exposure
2. Market Competition
3. Dependency on Revenue
4. Supply Chain Vulnerability
5. Regulatory Compliance
6. Technological Innovations
7. Dependence on Key Personnel
8. Cybersecurity Risks

Details are as follows –

Debt Exposure – Pacira has a total debt of US$755.7 million and US$316.4 million in cash as of June 2022. Excessive debt can lead to financial strain and even bankruptcy. Investors should monitor the company’s ability to manage its debt load and generate sufficient cash flow.

Market Competition – Pacira competes with other pharmaceutical companies for market share, so it must differentiate itself to maintain its edge.

Dependency on Revenue – Pacira’s financial stability is heavily dependent on the sales and market acceptance of its flagship products EXPAREL and ZILRETTA. Any decline in sales could pose a significant risk to the company’s financial health. Therefore, diversification of revenue streams is crucial to mitigate this risk.

Supply Chain Vulnerability – Pacira’s supply chain is at risk of disruption due to its dependence on a small number of wholesalers and manufacturing sites. This could have negative impacts on product availability and revenue.

Regulatory Compliance – Pharmaceutical industry has strict regulations. Pacira follows quality standards, safety protocols, and patent protection to avoid legal problems and financial penalties.

Technological Innovations – The industry changes quickly and Pacira must keep up to remain competitive. Not adapting to innovations could affect its market position.

Dependence on Key Personnel – The text highlights the critical role played by key executives and scientists in the success of Pacira. It also emphasizes that the departure of such personnel could lead to disruptions in the company’s operations and innovation.

Cybersecurity Risks – The text highlights the reality of cybersecurity threats in the digital world. It emphasizes that data breaches or system vulnerabilities can potentially harm a company’s reputation and finances.

Pacira BioSciences Stock Price Prediction 2030 (2024-2060)

Pacira BioSciences Inc Stock Price Prediction 2024 | Pacira BioSciences Inc Stock Forecast 2024

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $33.78, with a
• high projection of $39.54 and a
• low estimate of $25.40.

Pacira BioSciences Inc Stock Price Prediction 2025 | Pacira BioSciences Inc Stock Forecast 2025

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $50.81, with a
• high projection of $55.60 and a
• low estimate of $18.45.

Pacira BioSciences Inc Stock Price Prediction 2026 | Pacira BioSciences Inc Stock Forecast 2026

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $48.55, with a
• high projection of $71.38 and a
• low estimate of $39.48.

Pacira BioSciences Inc Stock Price Prediction 2027 | Pacira BioSciences Inc Stock Forecast 2027

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $46.98, with a
• high projection of $74.02 and a
• low estimate of $36.70.

Pacira BioSciences Inc Stock Price Prediction 2028 | Pacira BioSciences Inc Stock Forecast 2028

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $31.44, with a
• high projection of $51.21 and a
• low estimate of $27.55.

Pacira BioSciences Inc Stock Price Prediction 2029 | Pacira BioSciences Inc Stock Forecast 2029

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $18.02, with a
• high projection of $34.03 and a
• low estimate of $16.18.

Pacira BioSciences Inc Stock Price Prediction 2030 | Pacira BioSciences Inc Stock Forecast 2030

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $16.23, with a
• high projection of $33.26 and a
• low estimate of $13.85.

Pacira BioSciences Inc Stock Price Prediction 2035 | Pacira BioSciences Inc Stock Forecast 2035

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $14.90, with a
• high projection of $20.78 and a
• low estimate of $6.733.

Pacira BioSciences Inc Stock Price Prediction 2040 | Pacira BioSciences Inc Stock Forecast 2040

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $18.12, with a
• high projection of $25.55 and a
• low estimate of $10.70.

Pacira BioSciences Inc Stock Price Prediction 2045 | Pacira BioSciences Inc Stock Forecast 2045

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $10.56, with a
• high projection of $27.22 and a
• low estimate of $4.1572.

Pacira BioSciences Inc Stock Price Prediction 2050 | Pacira BioSciences Inc Stock Forecast 2050

Pacira Bioscience’s stock is anticipated to reach an  –

• average price of $9.6498, with a
• high projection of $41.46 and a
• low estimate of $6.6398.

Pacira BioSciences Inc Stock Price Prediction 2060 | Pacira BioSciences Inc Stock Forecast 2060

Pacira Bioscience’s stock is anticipated to reach an  –

• average price – will update soon
• high projection – will update soon
• low estimate – will update soon

Read More – Quantum Leap to Profits: IonQ Stock Price Prediction 2030 2025 2040 2050 – Positive Trends Unveiled

Who are the competitors of Pacira BioSciences Inc?

Pacira faces competition from established players and emerging startups in the pharmaceutical industry. Notable competitors include –

1. Supernus Pharmaceuticals (SUPN): A fellow small-cap medical company.
2. Assembly Biosciences (ASMB): Focused on innovative therapies.
3. OPKO Health (OPK): Engaged in diagnostics and drug development.
4. ALX Oncology (ALXO): Specializing in cancer treatments.
5. Corcept Therapeutics (CORT): Known for its cortisol receptor modulators.
6. Atea Pharmaceuticals (AVIR): Pioneering antiviral therapeutics.
7. Seres Therapeutics (MCRB): Advancing microbiome-based therapies.
8. Nektar Therapeutics (NKTR): Developing novel drugs.
9. Perrigo (PRGO): A diversified healthcare company.
10. Verona Pharma (VRNA): Focused on respiratory diseases.

Conclusion

Pacira BioSciences, Inc. is a leading provider of non-opioid pain management and regenerative health solutions with innovative products like EXPAREL and ZILRETTA. Despite market competition, revenue dependency, and regulatory challenges, the company’s commitment to patient well-being and plans for expansion make it an attractive investment choice in the ever-evolving healthcare sector.

We hope you will like the information given by us. And if you want more information related to stock prediction. You can read our article and stay with us so that you can know the prediction of more stocks in the future.

Also, do your due diligence and comment to us, whether you will invest in this stock or not. Till then Happy Investing.

Pacira BioSciences Stock Prediction FAQs

What is the current stock price of Pacira BioSciences Inc?

The current stock price of Pacira BioSciences, Inc. (NASDAQ: PCRX) is $29.85 USD1. The stock has a 52-week range between $25.93 and $48.601.

What is the market capitalization of Pacira BioSciences Inc?

As of February 28, 2024, Pacira BioSciences, Inc. has a market capitalization of approximately $1.50 billion USD. Pacira BioSciences is 4458th most valuable company globally by market cap.

What is the predicted upside for Pacira BioSciences’s stock price?

According to analysts – Based on their 12-month stock forecasts Pacira BioSciences’s stock has a predicted upside of 62.90%.

Which analysts cover Pacira BioSciences?

Raymond James and Wedbush have recently rated Pacira BioSciences.

What is the Pacira BioSciences Inc stock prediction for 2025?

Pacira BioSciences Inc Stock forecast 2025 minimum is $18.45 and the maximum is $55.60.

What is the Pacira BioSciences Inc stock prediction for 2030?

Pacira BioSciences Inc Stock forecast 2030 minimum is $13.85 and the maximum is $33.26.

Will Pacira BioSciences Inc stock reach $100?

Not sure as of now, it will totally depend upon company fundamental and technicals.

Is Pacira BioSciences Inc a good stock to buy?

Out of the 7 analysts who have reviewed PCRX, 2 of them (which is about 28.57%) strongly recommend buying PCRX, while the other 5 (which is about 71.43%) recommend buying it. None of the analysts suggest holding or selling PCRX.

Is Pacira BioSciences Inc a good investment? | Should you invest in Pacira BioSciences Inc?

Investing in this opportunity may carry a higher level of risk but has the potential for higher rewards over a longer period of time. It could be a promising investment for those with a long-term investment horizon.

Out of the 7 analysts who have reviewed PCRX, 2 of them (which is about 28.57%) strongly recommend buying PCRX, while the other 5 (which is about 71.43%) recommend buying it. None of the analysts suggest holding or selling PCRX.

Disclaimer

This article [Pacira BioSciences Stock Price Prediction 2025] contains information that may be useful for those interested in the stock market. However, it is important to note that we do not provide recommendations to buy or sell any stocks.

Investing in the stock market carries inherent risks, so it is crucial to conduct thorough research on any company before making any investment decisions.